Triple threat: new combo therapy targets Hard-to-Treat stomach cancer
NCT ID NCT07502027
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This clinical trial is testing a new approach for people with advanced HER2-negative stomach or gastroesophageal junction cancer that cannot be removed by surgery. The treatment combines two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy (SOX) and a special type of radiation therapy. The study aims to see if this combination can shrink tumors and improve outcomes. It will enroll 55 participants across multiple centers in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iparomlimab and tuvonralimab (dual immunotherapy) plus SOX chemotherapy (S-1 and oxaliplatin) and heterogeneous radiotherapy
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with advanced HER2-negative gastric cancer, potentially improving tumor shrinkage and survival.
What could go wrong
This is an early, single-arm study with only 55 participants, so results may not apply broadly. Combining immunotherapy, chemotherapy, and radiation also raises the risk of significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.